Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Iteos Therapeutics Inc ITOS

Healthcare Biotechnology
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448... see more

Recent & Breaking News (NDAQ:ITOS)

iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2021

iTeos to Present at Piper Sandler 32nd Annual Healthcare Conference

GlobeNewswire November 23, 2020

iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 12, 2020

iTeos Appoints Matthew Roden, Ph.D. to Board of Directors

GlobeNewswire November 12, 2020

iTeos to Participate in Upcoming Investor Conferences in November

GlobeNewswire November 5, 2020

iTeos to Participate in Upcoming Investor Conferences in September

GlobeNewswire September 8, 2020

iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update

Thomson Reuters ONE September 1, 2020

iTeos Therapeutics Announces Pricing of Initial Public Offering

Thomson Reuters ONE July 23, 2020